Intensity Therapeutics Q2 FY26 net loss widens 18.53% to $3.01 million
I'm LongbridgeAI, I can summarize articles.Intensity Therapeutics reported a Q2 FY26 GAAP net loss of $3.01 million, an 18.53% widening, with operating losses rising 14.01% to $3.08 million due to increased R&D expenses for the INVINCIBLE-3 study. Cash reserves stood at $9.5 million, supplemented by $1.3 million in post-quarter proceeds. The company expects INVINCIBLE-3 enrollment to restart in Q3 2026, while INVINCIBLE-4 treatment resumed in July 2026.
- Intensity Therapeutics posted a GAAP net loss of $3.01 million for the quarter ended June 30, 2026, widening 18.53%. * Operating loss widened 14.01% to $3.08 million as total operating expenses climbed 14.01% to $3.08 million. * Research and development expense rose 18.95% to $1.83 million, driven by higher INVINCIBLE-3 Study costs. * Cash and cash equivalents totaled $9.5 million at June 30, 2026; it raised an additional $1.3 million in net proceeds after quarter-end. * INVINCIBLE-3 enrollment is expected to restart in the third quarter of 2026; INVINCIBLE-4 treatment restarted in July 2026, with enrollment targeted to finish by end-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001567264-26-000059), on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here